REPLIGEN CORPRGENEarnings & Financial Report
Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...
Revenue
$154.1M
Gross Profit
$76.8M
Operating Profit
$1.5M
Net Profit
$3.3M
Gross Margin
49.8%
Operating Margin
1.0%
Net Margin
2.2%
YoY Growth
-3.2%
EPS
$0.06
Financial Flow
REPLIGEN CORP Q2 2024 Financial Summary
REPLIGEN CORP reported revenue of $154.1M (down 3.2% YoY) for Q2 2024, with a net profit of $3.3M (down 83.4% YoY) (2.2% margin). Cost of goods sold was $77.3M, operating expenses totaled $75.3M.
Key Financial Metrics
| Total Revenue | $154.1M |
|---|---|
| Net Profit | $3.3M |
| Gross Margin | 49.8% |
| Operating Margin | 1.0% |
| Report Period | Q2 2024 |
REPLIGEN CORP Annual Revenue by Year
REPLIGEN CORP annual revenue history includes year-by-year totals (for example, 2025 revenue was $738.3M).
| Year | Annual Revenue |
|---|---|
| 2025 | $738.3M |
| 2024 | $634.4M |
| 2023 | $632.4M |
| 2022 | $801.5M |
REPLIGEN CORP Quarterly Revenue & Net Profit History
REPLIGEN CORP results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $197.9M | +13.6% | $13.3M | 6.7% |
| Q3 2025 | $188.8M | +21.9% | $14.9M | 7.9% |
| Q2 2025 | $182.4M | +18.4% | $14.9M | 8.2% |
| Q1 2025 | $169.2M | +11.8% | $5.8M | 3.4% |
| Q4 2024 | $174.1M | +11.8% | $-30.3M | -17.4% |
| Q3 2024 | $154.9M | +9.7% | $-654.0K | -0.4% |
| Q2 2024 | $154.1M | -3.2% | $3.3M | 2.2% |
| Q1 2024 | $151.3M | -17.1% | $2.1M | 1.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $151.3M | $154.1M | $154.9M | $174.1M | $169.2M | $182.4M | $188.8M | $197.9M |
| YoY Growth | -17.1% | -3.2% | 9.7% | 11.8% | 11.8% | 18.4% | 21.9% | 13.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $2.85B | $2.86B | $2.83B | $2.83B | $2.85B | $2.90B | $2.92B | $2.95B |
| Liabilities | $878.7M | $875.6M | $814.0M | $856.9M | $866.7M | $839.9M | $840.6M | $843.6M |
| Equity | $1.97B | $1.99B | $2.02B | $1.97B | $1.99B | $2.06B | $2.08B | $2.11B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $44.7M | $42.2M | $49.3M | $39.2M | $15.0M | $28.6M | $48.1M | $25.7M |